News

NMS Group S.p.A. has approved the 2021 Financial Statements with positive outlook for 2022
Nerviano, 29 June 2022
The Board of Directors of NMS Group S.p.A has approved today the company’s annual financial report, including the consolidated financial statements of the Group as of 31 December 2021.
(Click the title for the complete article)
NMS Group S.p.A. Announces Resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl; Hugues Dolgos – CEO of NMS Group S.p.A. – Appointed Interim CEO
Nerviano, 5 May 2022
NMS Group SpA today announced that its CEO, Hugues Dolgos, has accepted the resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl, effective 31 May 2022. Hugues Dolgos will act as interim CEO for both companies. A search for a permanent CEO will begin shortly. (Click the title for the complete article)
Member of European Parliament Isabella Tovaglieri and Chairman of the Health Commission of Lombardy Region Emanuele Monti led delegation to visit NMS Group in Nerviano, Lombardy
Nerviano, 7 February 2022
NMS Group, the center of excellence of oncology research and development in the heart of the Lombardy region is honored to receive the visit by Ms. Isabella Tovaglieri, Member of the European Parliament, Mr. Emanuele Monti, Chairman of the Health Commission of Lombardy Region, Mr. Loredano Pollegioni, Chairman of FRRB (Fondazione Regionale per la Ricerca Biomedica), Mr. Luigi Cajazzo, Managing director of FRRB and Mr. Massimiliano Amato, Board member of NMS Group SpA today. The delegation was warmly welcomed by Dr. Hugues Dolgos, the newly appointed CEO of NMS Group and CEOs of the Group’s subsidiaries Dr. Guoxian (Gregory) Wu, Mr. Angelo Colombo, and Mr. Giuseppe Vivolo. (Click the title for the complete article)
NMS Group S.p.A. announces appointment of New CEO Hugues Dolgos and New Board of Directors and CEO of its Subsidiaries
Nerviano, 17 January 2022
The Shareholders’ Meeting of NMS Group S.p.A. (the “Company”) has appointed new Board of Directors for a three-year term. Tak-Wai (David) Wong has been named Chairman of the Board. Other newly appointed board members are Hugues Dolgos, Raj Sundar, Jianghua (Peter) Zhao, Liping Meng, and Massimiliano Amato.
Following the Shareholders’ Meeting, the Company’s newly formed Board of Directors approved a new governance to accelerate the progression of the portfolio, to strengthen the competitive positions of Accelera and NerPharMa, and to optimize and deliver concrete values for its patients, shareholders, employees and community. Dr. Hugues Dolgos, a seasoned biopharma leader with over 20 years of experience across the R&D value chain from new concept to post approval in multiple therapeutic areas and a proven track record in oncology and immuno-oncology, was appointed as Chief Executive Officer (“CEO”) of the Company, effective immediately. (Click the title to read the complete article)
Pharma Tech Outlook Names NMS Group a Top Drug Discovery and Development Solution Provider in Europe 2021
Nerviano, 29 September 2021
NMS Group is proud to be named by Pharma Tech Outlook as Top drug discovery and development solution providers in Europe for 2021 and featured in the cover of this special issue. The annual list showcases companies that are providing cutting-edge drug discovery and development tech solutions and services. Determined by a panel of experts and members of Pharma Tech Outlook’s editorial board, NMS Group has come on top in terms of its ability to innovate in drug R&D process, and to meet client requirements, through support and customization.
(Click the title for the complete article)
Accelera and BiomimX: Commercial agreement
Nerviano, 30 June 2021 Accelera Srl and BiomimX® Srl have signed a non-exclusive commercial agreement following an intense scientific collaboration aimed at introducing and applying new technological solutions to the drug discovery process. The...
Accelera and CROSS: an integrated solution for Pre-clinical to Clinical transition
Nerviano, 17 May 2021 The relationship between Accelera and CROss Alliance® started a decade ago and since then we have renewed our collaboration during the years. Our specializations, preclinical and early phase clinical development respectively, our shared...